229 related articles for article (PubMed ID: 15621775)
1. Adoptive immunotherapy for EBV-associated malignancies.
Gottschalk S; Heslop HE; Rooney CM
Leuk Lymphoma; 2005 Jan; 46(1):1-10. PubMed ID: 15621775
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Epstein-Barr virus-associated malignancies with specific T cells.
Gottschalk S; Heslop HE; Roon CM
Adv Cancer Res; 2002; 84():175-201. PubMed ID: 11883527
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for Epstein-Barr virus-associated cancers in children.
Straathof KC; Bollard CM; Rooney CM; Heslop HE
Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Epstein-Barr virus-associated tumors.
Comito MA; Sun Q; Lucas KG
Leuk Lymphoma; 2004 Oct; 45(10):1981-7. PubMed ID: 15370241
[TBL] [Abstract][Full Text] [Related]
6. Adoptive T-Cell Immunotherapy.
Gottschalk S; Rooney CM
Curr Top Microbiol Immunol; 2015; 391():427-54. PubMed ID: 26428384
[TBL] [Abstract][Full Text] [Related]
7. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
Davis JE; Moss DJ
Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
[TBL] [Abstract][Full Text] [Related]
8. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
Sun Q; Burton R; Reddy V; Lucas KG
Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
[TBL] [Abstract][Full Text] [Related]
11. Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease.
Huls MH; Rooney CM; Heslop HE
Acta Haematol; 2003; 110(2-3):149-53. PubMed ID: 14583675
[TBL] [Abstract][Full Text] [Related]
12. EBV-related lymphomas: new approaches to treatment.
Kanakry JA; Ambinder RF
Curr Treat Options Oncol; 2013 Jun; 14(2):224-36. PubMed ID: 23549980
[TBL] [Abstract][Full Text] [Related]
13. Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.
Hoffmann T; Russell C; Vindelov L
APMIS; 2002 Feb; 110(2):148-57. PubMed ID: 12064870
[TBL] [Abstract][Full Text] [Related]
14. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
[TBL] [Abstract][Full Text] [Related]
15. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Epstein-Barr virus-associated malignancies.
Long HM; Parsonage G; Fox CP; Lee SP
Drug News Perspect; 2010 May; 23(4):221-8. PubMed ID: 20520851
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for EBV-associated malignancies.
Merlo A; Turrini R; Dolcetti R; Zanovello P; Rosato A
Int J Hematol; 2011 Mar; 93(3):281-293. PubMed ID: 21336546
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
Lucas KG; Salzman D; Garcia A; Sun Q
Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T cells and EBV associated malignancies.
Li J; Qian CN; Zeng YX
Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572
[TBL] [Abstract][Full Text] [Related]
20. Adoptive cell therapy against EBV-related malignancies: a survey of clinical results.
Merlo A; Turrini R; Dolcetti R; Zanovello P; Amadori A; Rosato A
Expert Opin Biol Ther; 2008 Sep; 8(9):1265-94. PubMed ID: 18694349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
